Boehringer Ingelheim To Develop More Than 10 Biosimilars In Japan
This article was originally published in PharmAsia News
Executive Summary
Boehringer Ingelheim plans to develop more than 10 biosimilars and start clinical trials on three products this year, according to Biopharmaceuticals Chief Wolfram Carius.